Duncker Streett & Co. Inc. Grows Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Duncker Streett & Co. Inc. raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 67.9% during the second quarter, according to its most recent filing with the SEC. The firm owned 539 shares of the company’s stock after purchasing an additional 218 shares during the period. Duncker Streett & Co. Inc.’s holdings in Medpace were worth $222,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Rise Advisors LLC bought a new stake in shares of Medpace in the 1st quarter valued at about $27,000. Mather Group LLC. acquired a new stake in shares of Medpace in the 1st quarter worth $28,000. GAMMA Investing LLC purchased a new position in Medpace during the 4th quarter worth $30,000. Fidelis Capital Partners LLC acquired a new position in Medpace during the 1st quarter valued at about $31,000. Finally, J.Safra Asset Management Corp raised its stake in Medpace by 87.0% in the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after buying an additional 47 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on MEDP shares. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research report on Wednesday, July 24th. TD Cowen reduced their target price on Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research report on Tuesday, July 23rd. Mizuho initiated coverage on shares of Medpace in a report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price target on the stock. Finally, Guggenheim decreased their price objective on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $423.00.

Medpace Trading Down 2.9 %

Medpace stock opened at $355.27 on Friday. The firm has a market cap of $11.01 billion, a PE ratio of 36.22, a P/E/G ratio of 1.85 and a beta of 1.36. The stock’s 50 day simple moving average is $397.14 and its two-hundred day simple moving average is $396.90. Medpace Holdings, Inc. has a 12 month low of $227.21 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, July 22nd. The company reported $2.75 EPS for the quarter, beating analysts’ consensus estimates of $2.54 by $0.21. The firm had revenue of $528.10 million for the quarter, compared to analysts’ expectations of $528.41 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The company’s quarterly revenue was up 14.6% on a year-over-year basis. During the same period last year, the firm earned $1.93 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 11.66 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.